Skip to main content

Articles

Page 3 of 65

  1. Vascular invasion is a major route for intrahepatic and distant metastasis in hepatocellular carcinoma (HCC) and is a strong negative prognostic factor. Circular RNAs (circRNAs) play important roles in tumorig...

    Authors: Liangliang Xu, Peng Wang, Li Li, Lian Li, Yang Huang, Yanfang Zhang, Xiaobo Zheng, Pengsheng Yi, Ming Zhang and Mingqing Xu
    Citation: Molecular Cancer 2023 22:174
  2. Authors: Tao Xie, Du-jiang Fu, Zhi-min Li, Dao-jun Lv, Xian-Lu Song, Yu-zhong Yu, Chong Wang, Kang-jin Li, Baoqian Zhai, Jiacheng Wu, Ning-Han Feng and Shan-Chao Zhao
    Citation: Molecular Cancer 2023 22:173

    The original article was published in Molecular Cancer 2022 21:173

  3. Cancer stem cells (CSCs), initially identified in leukemia in 1994, constitute a distinct subset of tumor cells characterized by surface markers such as CD133, CD44, and ALDH. Their behavior is regulated throu...

    Authors: Zhen Zeng, Minyang Fu, Yuan Hu, Yuquan Wei, Xiawei Wei and Min Luo
    Citation: Molecular Cancer 2023 22:172
  4. Cancer-associated fibroblasts (CAFs) are a heterogeneous cell population that plays a crucial role in remodeling the tumor microenvironment (TME). Here, through the integrated analysis of spatial and single-ce...

    Authors: Chenxi Ma, Chengzhe Yang, Ai Peng, Tianyong Sun, Xiaoli Ji, Jun Mi, Li Wei, Song Shen and Qiang Feng
    Citation: Molecular Cancer 2023 22:170
  5. The use of nanotechnology has the potential to revolutionize the detection and treatment of cancer. Developments in protein engineering and materials science have led to the emergence of new nanoscale targetin...

    Authors: Mohammad Chehelgerdi, Matin Chehelgerdi, Omer Qutaiba B. Allela, Renzon Daniel Cosme Pecho, Narayanan Jayasankar, Devendra Pratap Rao, Tamilanban Thamaraikani, Manimaran Vasanthan, Patrik Viktor, Natrayan Lakshmaiya, Mohamed J. Saadh, Ayesha Amajd, Mabrouk A. Abo-Zaid, Roxana Yolanda Castillo-Acobo, Ahmed H. Ismail, Ali H. Amin…
    Citation: Molecular Cancer 2023 22:169
  6. Skin cancer is a global threat to the healthcare system and is estimated to incline tremendously in the next 20 years, if not diagnosed at an early stage. Even though it is curable at an early stage, novel dru...

    Authors: Nazeer Hasan, Arif Nadaf, Mohammad Imran, Umme Jiba, Afsana Sheikh, Waleed H. Almalki, Salem Salman Almujri, Yousuf Hussain Mohammed, Prashant Kesharwani and Farhan Jalees Ahmad
    Citation: Molecular Cancer 2023 22:168
  7. Interferon-gamma (IFNγ) exerts potent growth inhibitory effects on a wide range of cancer cells through unknown signaling pathways. We pursued complementary screening approaches to characterize the growth inhi...

    Authors: Ameya Champhekar, Rachel Heymans, Justin Saco, Guillem Turon Font, Cynthia Gonzalez, Anne Gao, John Pham, June Lee, Ryan Maryoung, Egmidio Medina, Katie M. Campbell, Daniel Karin, David Austin, Robert Damioseaux and Antoni Ribas
    Citation: Molecular Cancer 2023 22:165

    The Correction to this article has been published in Molecular Cancer 2024 23:29

  8. To address the shortcomings of current hepatocellular carcinoma (HCC) surveillance tests, we set out to find HCC-specific methylation markers and develop a highly sensitive polymerase chain reaction (PCR)-base...

    Authors: Si-Cho Kim, Da-Won Kim, Eun Ju Cho, Jin-Young Lee, Jiwon Kim, Chaesun Kwon, Jeongsil Kim-Ha, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Won Kim, Woojin Kim, Hyunsoo Kim, Yoon Jun Kim…
    Citation: Molecular Cancer 2023 22:164
  9. Lysine crotonylation (Kcr) is up-regulation in colorectal cancer (CRC) tissues, while its specific contribution remains uncertain. This study aimed to elucidate the role and mechanism of crotonylation on Lys27...

    Authors: Meijian Liao, Xiaolin Sun, Wendan Zheng, Mengdi Wu, Yifan Wang, Jia Yao, Yu Ma, Shoucui Gao and Dongsheng Pei
    Citation: Molecular Cancer 2023 22:163
  10. Genetic signatures have added a molecular dimension to prognostics and therapeutic decision-making. However, tumour heterogeneity in prostate cancer and current sampling methods could confound accurate assessm...

    Authors: Sandy Figiel, Wencheng Yin, Dimitrios Doultsinos, Andrew Erickson, Ninu Poulose, Reema Singh, Anette Magnussen, Thineskrishna Anbarasan, Renuka Teague, Mengxiao He, Joakim Lundeberg, Massimo Loda, Clare Verrill, Richard Colling, Pelvender S. Gill, Richard J. Bryant…
    Citation: Molecular Cancer 2023 22:162
  11. Fecal microRNAs represent promising molecules with potential clinical interest as non-invasive diagnostic and prognostic biomarkers. Colorectal cancer (CRC) screening based on the fecal immunochemical test (FI...

    Authors: Einar Birkeland, Giulio Ferrero, Barbara Pardini, Sinan U. Umu, Sonia Tarallo, Sara Bulfamante, Geir Hoff, Carlo Senore, Trine B Rounge and Alessio Naccarati
    Citation: Molecular Cancer 2023 22:161
  12. Lipid-based polymeric nanoparticles are the highly popular carrier systems for cancer drug therapy. But presently, detailed investigations have revealed their flaws as drug delivery carriers. Lipid polymer hyb...

    Authors: Kavita R. Gajbhiye, Rajesh Salve, Mahavir Narwade, Afsana Sheikh, Prashant Kesharwani and Virendra Gajbhiye
    Citation: Molecular Cancer 2023 22:160
  13. Despite centuries since the discovery and study of cancer, cancer is still a lethal and intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much attention as a pivotal compone...

    Authors: Hao Zhang, Xinghai Yue, Zhe Chen, Chao Liu, Wantao Wu, Nan Zhang, Zaoqu Liu, Liping Yang, Qing Jiang, Quan Cheng, Peng Luo and Guodong Liu
    Citation: Molecular Cancer 2023 22:159
  14. The Eyes Absent (EYA) family of proteins is an atypical group of four dual-functioning protein phosphatases (PP), which have been linked to many vital cellular processes and organogenesis pathways. The four fa...

    Authors: Bárbara de la Peña Avalos, Romain Tropée, Pascal H. G. Duijf and Eloïse Dray
    Citation: Molecular Cancer 2023 22:158
  15. Although colonoscopy is the standard screening test for colorectal cancer (CRC), its use is limited by a poor compliance rate, the need for extensive bowel preparation, and the risk of complications. As an alt...

    Authors: Fuqiang Zhao, Ping Bai, Jianfeng Xu, Zitong Li, Shan Muhammad, Diange Li, Zeyue Zhang, Yibo Gao and Qian Liu
    Citation: Molecular Cancer 2023 22:157
  16. Targetable molecular drivers of gastric cancer (GC) metastasis remain largely unidentified, leading to limited targeted therapy options for advanced GC. We aimed to identify molecular drivers for metastasis an...

    Authors: Jong-Wan Kwon, Jeong-Seop Oh, Sang Hyeok Seok, Hyeok-Won An, Yu Jin Lee, Na Yun Lee, Taehun Ha, Hyeon Ah Kim, Gyeong Min Yoon, Sung Eun Kim, Pu-Reum Oh, Su-Hyung Lee, Dominic C. Voon, Dae-Yong Kim and Jun Won Park
    Citation: Molecular Cancer 2023 22:156
  17. Among digestive tract tumours, pancreatic ductal adenocarcinoma (PDAC) shows the highest mortality trend. Moreover, although PDAC metastasis remains a leading cause of cancer-related deaths, the biological mec...

    Authors: Zhongjie Zhao, Wenbo Yang, Rui Kong, Yangyang Zhang, Le Li, Zengfu Song, Hongze Chen, Yan Luo, Tao Zhang, Chundong Cheng, Guanqun Li, Danxi Liu, Xinglong Geng, Hua Chen, Yongwei Wang, Shangha Pan…
    Citation: Molecular Cancer 2023 22:152
  18. Bladder cancer (BCa) is the fourth most common malignant tumor with a poor prognosis worldwide. Further exploration and research are needed to unmask the underlying roles and molecular mechanisms of circular R...

    Authors: Bo Xie, Juntao Lin, Xianwu Chen, Xuejian Zhou, Yan Zhang, Mengjing Fan, Jiayong Xiang, Ning He, Zhenghui Hu and Feifan Wang
    Citation: Molecular Cancer 2023 22:151
  19. Recent advances in immuno-oncology have opened up new and impressive treatment options for cancer. Notwithstanding, overcoming the limitations of the current FDA-approved therapies with monoclonal antibodies (...

    Authors: Ismael Rodriguez, Justyna Kocik-Krol, Lukasz Skalniak, Bogdan Musielak, Aneta Wisniewska, Agnieszka Ciesiołkiewicz, Łukasz Berlicki, Jacek Plewka, Przemyslaw Grudnik, Malgorzata Stec, Maciej Siedlar, Tad A. Holak and Katarzyna Magiera-Mularz
    Citation: Molecular Cancer 2023 22:150
  20. The term “metastatic cascade” defines a process whereby few tumor cells complete a sequence of steps to leave the primary tumor to reach one or more sites elsewhere in the body, usually through the bloodstream...

    Authors: Veronica Marabitti, Ignazio Caruana and Francesca Nazio
    Citation: Molecular Cancer 2023 22:149
  21. Neutrophils, the most prevalent innate immune cells in humans, have garnered significant attention in recent years due to their involvement in cancer progression. This comprehensive review aimed to elucidate t...

    Authors: Siyao Liu, Wenchuan Wu, Yueshan Du, Hanlin Yin, Qiangda Chen, Weisheng Yu, Wenquan Wang, Jun Yu, Liang Liu, Wenhui Lou and Ning Pu
    Citation: Molecular Cancer 2023 22:148
  22. Gastric adenocarcinoma (GAC) is a lethal disease characterized by genomic and clinical heterogeneity. By integrating 8 previously established genomic signatures for GAC subtypes, we identified 6 clinically and...

    Authors: Yun Seong Jeong, Young-Gyu Eun, Sung Hwan Lee, Sang-Hee Kang, Sun Young Yim, Eui Hyun Kim, Joo Kyung Noh, Bo Hwa Sohn, Seon Rang Woo, Moonkyoo Kong, Deok Hwa Nam, Hee-Jin Jang, Hyun-Sung Lee, Shumei Song, Sang Cheul Oh, Jeeyun Lee…
    Citation: Molecular Cancer 2023 22:147
  23. Multidrug resistance renders treatment failure in a large proportion of head and neck squamous cell carcinoma (HNSCC) patients that require multimodal therapy involving chemotherapy in conjunction with surgery...

    Authors: Neha Khera, Asvika Soodhalaagunta Rajkumar, Khlood Abdulkader M Alkurdi, Zhiao Liu, Hong Ma, Ahmad Waseem and Muy-Teck Teh
    Citation: Molecular Cancer 2023 22:146
  24. Immunotherapy has recently emerged as a treatment strategy which stimulates the human immune system to kill tumor cells. Tumor immunotherapy is based on immune editing, which enhances the antigenicity of tumor...

    Authors: Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu and Xi Gu
    Citation: Molecular Cancer 2023 22:145

    The Correction to this article has been published in Molecular Cancer 2023 22:154

  25. Authors: Zhenlong Yu, Wei Guo, Xiaochi Ma, Baojing Zhang, Peipei Dong, Lin Huang, Xiuli Wang, Chao Wang, Xiaokui Huo, Wendan Yu, Canhui Yi, Yao Xiao, Wenjing Yang, Yu Qin, Yuhui Yuan, Songshu Meng…
    Citation: Molecular Cancer 2023 22:144

    The original article was published in Molecular Cancer 2014 13:203

  26. Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the developme...

    Authors: Qin Yu, Wenhao Fu, Yutang Fu, Wenjing Ye, Huiqiong Yan, Zecheng Yu, Ruirui Li, Yili Cai, Yuxin Chen, Lingyun Wang, Xianqiao Wei, Yangkun Chen, Yuheng Zhang, Huazhong Ying, Furong Tang, Fangwei Dai…
    Citation: Molecular Cancer 2023 22:143
  27. Recent introduction of monoclonal antibodies targeting immune checkpoints to harness antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic success of immune checkpoint blockade ...

    Authors: Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Rocío Granda-Díaz, Alejandra Martínez-Pérez, Candelaria Aguilar-García, Juan P. Rodrigo, Juana M. García-Pedrero and Segundo Gonzalez
    Citation: Molecular Cancer 2023 22:142
  28. Recent advances in neoantigen research have accelerated the development of tumor immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody-based therapies, particularly for solid ...

    Authors: Jiangping Li, Zhiwen Xiao, Donghui Wang, Lei Jia, Shihong Nie, Xingda Zeng and Wei Hu
    Citation: Molecular Cancer 2023 22:141
  29. Authors: Tao Zhang, Rong Qu, Shingpan Chan, Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun…
    Citation: Molecular Cancer 2023 22:139

    The original article was published in Molecular Cancer 2020 19:90

  30. The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to...

    Authors: Antonino Glaviano, Aaron S. C. Foo, Hiu Y. Lam, Kenneth C. H. Yap, William Jacot, Robert H. Jones, Huiyan Eng, Madhumathy G. Nair, Pooyan Makvandi, Birgit Geoerger, Matthew H. Kulke, Richard D. Baird, Jyothi S. Prabhu, Daniela Carbone, Camilla Pecoraro, Daniel B. L. Teh…
    Citation: Molecular Cancer 2023 22:138
  31. Glycolytic reprogramming is one of the most important features of cancer and plays an integral role in the progression of cancer. In cancer cells, changes in glucose metabolism meet the needs of self-prolifera...

    Authors: Shi-Wei Yue, Hai-Ling Liu, Hong-Fei Su, Chu Luo, Hui-Fang Liang, Bi-Xiang Zhang and Wei Zhang
    Citation: Molecular Cancer 2023 22:137
  32. New therapies are urgently needed in melanoma, particularly in late-stage patients not responsive to immunotherapies and kinase inhibitors. To uncover novel potentiators of T cell anti-tumor immunity, we carri...

    Authors: Paweł Stachura, Wei Liu, Haifeng C. Xu, Agnès Wlodarczyk, Olivia Stencel, Piyush Pandey, Melina Vogt, Sanil Bhatia, Daniel Picard, Marc Remke, Karl S. Lang, Dieter Häussinger, Bernhard Homey, Philipp A. Lang, Arndt Borkhardt and Aleksandra A. Pandyra
    Citation: Molecular Cancer 2023 22:136
  33. Authors: Hyunbin D. Huh, Yujin Sub, Jongwook Oh, Ye Eun Kim, Ju Young Lee, Hwa‑Ryeon Kim, Soyeon Lee, Hannah Lee, Sehyung Pak, Sebastian E. Amos, Danielle Vahala, Jae Hyung Park, Ji Eun Shin, So Yeon Park, Han Sang Kim, Young Hoon Roh…
    Citation: Molecular Cancer 2023 22:135

    The original article was published in Molecular Cancer 2023 22:63

  34. Authors: Jinpeng Du, Tian Lan, Haotian Liao, Xuping Feng, Xing Chen, Wenwei Liao, Guimin Hou, Lin Xu, Qingbo Feng, Kunlin Xie, Mingheng Liao, Xiangzheng Chen, Jiwei Huang, Kefei Yuan and Yong Zeng
    Citation: Molecular Cancer 2023 22:134

    The original article was published in Molecular Cancer 2022 21:18

  35. Prostate cancer (PCa) is a common and fatal type of cancer in men. Metastatic PCa (mPCa) is a major factor contributing to its lethality, although the mechanisms remain poorly understood. PTEN is one of the mo...

    Authors: Jan Pencik, Cecile Philippe, Michaela Schlederer, Emine Atas, Matteo Pecoraro, Sandra Grund-Gröschke, Wen (Jess) Li, Amanda Tracz, Isabel Heidegger, Sabine Lagger, Karolína Trachtová, Monika Oberhuber, Ellen Heitzer, Osman Aksoy, Heidi A. Neubauer, Bettina Wingelhofer…
    Citation: Molecular Cancer 2023 22:133
  36. Chimeric antigen receptor (CAR) -T cell therapy is an efficient therapeutic strategy for specific hematologic malignancies. However, positive outcomes of this novel therapy in treating solid tumors are curtail...

    Authors: Jian Chen, Tianchuan Zhu, Guanmin Jiang, Qi Zeng, Zhijian Li and Xi Huang
    Citation: Molecular Cancer 2023 22:131
  37. The reversible oxidation-reduction homeostasis mechanism functions as a specific signal transduction system, eliciting related physiological responses. Disruptions to redox homeostasis can have negative conseq...

    Authors: Yuqing Ren, Ruizhi Wang, Siyuan Weng, Hui Xu, Yuyuan Zhang, Shuang Chen, Shutong Liu, Yuhao Ba, Zhaokai Zhou, Peng Luo, Quan Cheng, Qin Dang, Zaoqu Liu and Xinwei Han
    Citation: Molecular Cancer 2023 22:130
  38. This Phase 1 study evaluates the intra- and peritumoral administration by convection enhanced delivery (CED) of human recombinant Bone Morphogenetic Protein 4 (hrBMP4) – an inhibitory regulator of cancer stem ...

    Authors: Eelke M. Bos, Elena Binda, Iris S.C. Verploegh, Eva Wembacher, Daphna Hoefnagel, Rutger K. Balvers, Anne L. Korporaal, Andrea Conidi, Esther A. H. Warnert, Nadia Trivieri, Alberto Visioli, Paola Zaccarini, Laura Caiola, Rogier van Wijck, Peter van der Spek, Danny Huylebroeck…
    Citation: Molecular Cancer 2023 22:129
  39. Protein regulator of cytokinesis 1 (PRC1) is involved in cytokinesis. Growing evidence suggests the association of PRC1 with multiple cancers. Here, we unveil that, in 28 cancer types, PRC1 is higher expressed...

    Authors: Sijing Li, Omar Motiño, Flavia Lambertucci, Isabelle Martins, Li Sun and Guido Kroemer
    Citation: Molecular Cancer 2023 22:128
  40. Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to...

    Authors: Javier Martin-Broto, Claudia Valverde, Nadia Hindi, Bruno Vincenzi, Javier Martinez-Trufero, Giovanni Grignani, Antoine Italiano, Javier Lavernia, Ana Vallejo, Paolo Dei Tos, Francois Le Loarer, Ricardo Gonzalez-Campora, Rafael Ramos, Diana Hernández-Jover, Antonio Gutierrez, Cesar Serrano…
    Citation: Molecular Cancer 2023 22:127
  41. Children with birth defects (BD) express distinct clinical features that often have various medical consequences, one of which is predisposition to the development of cancers. Identification of the underlying ...

    Authors: Yichuan Liu, Hui-Qi Qu, Xiao Chang, Frank D Mentch, Haijun Qiu, Xiang Wang, Amir Hossein Saeidian, Deborah Watson, Joseph Glessner and Hakon Hakonarson
    Citation: Molecular Cancer 2023 22:126

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    91 days submission to accept (Median)

    2023 Usage 
    3,569,666 downloads
    2,070 Altmetric mentions